Rezolute (RZLT) EBITDA (2012 - 2026)
Rezolute recorded quarterly EBITDA of -$16.3 million in Q1 2026, up 28.29% quarter-over-quarter from -$22.8 million in Q4 2025, and up 13.74% year-over-year from -$14.4 million in Q1 2025.
Rezolute's EBITDA history runs 15 years deep, the most recent figure standing at -$16.3 million for Q1 2026.
- In Q1 2026, EBITDA rose 13.74% year-over-year to -$16.3 million; the TTM figure through Mar 2026 stood at -$81.6 million (down 12.03% YoY), while the FY2025 annual figure was -$74.3 million, down 9.02% from the prior year.
- EBITDA came in at -$16.3 million for Q1 2026 at Rezolute, up from -$22.8 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$9.4 million in Q2 2022 to a low of -$24.4 million in Q2 2025.
- A 5-year average of -$16.0 million and a median of -$15.8 million in 2023 frame the typical range for EBITDA.
- Across the five-year window, EBITDA plunged 104.41% in 2022 and rose 13.74% in 2026, its largest moves.
- Rezolute's EBITDA stood at -$13.6 million in 2022, then retreated by 0.86% to -$13.7 million in 2023, then fell by 16.69% to -$16.0 million in 2024, then slumped by 42.75% to -$22.8 million in 2025, then increased by 28.29% to -$16.3 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$16.3 million, -$22.8 million, and -$18.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | -16.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.33 Mn |
| Dec 31, 2025 | -22.78 Mn |
| Sep 30, 2025 | -18.09 Mn |
| Jun 30, 2025 | -24.44 Mn |
| Mar 31, 2025 | -18.94 Mn |
| Dec 31, 2024 | -15.96 Mn |
| Sep 30, 2024 | -15.01 Mn |
| Jun 30, 2024 | -22.98 Mn |
| Mar 31, 2024 | -17.08 Mn |
| Dec 31, 2023 | -13.67 Mn |
| Sep 30, 2023 | -14.46 Mn |
| Jun 30, 2023 | -12.95 Mn |
| Mar 31, 2023 | -15.80 Mn |
| Dec 31, 2022 | -13.56 Mn |
| Sep 30, 2022 | -9.83 Mn |
| Jun 30, 2022 | -9.42 Mn |
| Mar 31, 2022 | -11.21 Mn |
| Dec 31, 2021 | -12.15 Mn |
| Sep 30, 2021 | -7.64 Mn |
| Jun 30, 2021 | -6.64 Mn |
| Mar 31, 2021 | -5.48 Mn |
| Dec 31, 2020 | -7.15 Mn |
| Sep 30, 2020 | -3.62 Mn |
| Jun 30, 2020 | -3.55 Mn |
| Mar 31, 2020 | -5.07 Mn |
| Dec 31, 2019 | -6.72 Mn |
| Sep 30, 2019 | -5.18 Mn |
| Jun 30, 2019 | -3.18 Mn |
| Mar 31, 2019 | -17.04 Mn |
| Dec 31, 2018 | -3.16 Mn |
| Sep 30, 2018 | -2.56 Mn |
| Jun 30, 2018 | -11.31 Mn |
| Mar 31, 2018 | -4.95 Mn |
| Dec 31, 2017 | -5.75 Mn |
| Sep 30, 2017 | -6.72 Mn |
| Jun 30, 2017 | -6.22 Mn |
| Mar 31, 2017 | -5.39 Mn |
| Dec 31, 2016 | -4.89 Mn |
| Sep 30, 2016 | -3.82 Mn |
| Jun 30, 2016 | -3.87 Mn |
| Mar 31, 2016 | -3.72 Mn |
| Dec 31, 2015 | -4.07 Mn |
| Sep 30, 2015 | -3.30 Mn |
| Jun 30, 2015 | -3.09 Mn |
| Mar 31, 2015 | -2.30 Mn |
| Dec 31, 2014 | -3.07 Mn |
| Sep 30, 2014 | -2.21 Mn |
| Jun 30, 2014 | -2.23 Mn |
| Mar 31, 2014 | -1.60 Mn |
| Dec 31, 2013 | -650,118.00 |
| Sep 30, 2013 | -700,903.00 |
| Jun 30, 2013 | -1.01 Mn |
| Mar 31, 2013 | -4.05 Mn |
| Dec 31, 2012 | -500,065.00 |
| Sep 30, 2012 | -542,882.00 |
| Jun 30, 2012 | -227,901.00 |
| Mar 31, 2012 | -94,596.00 |